Non-compliance with pregnancy prevention recommendations for isotretinoin in Korea between 2019-2020

被引:4
作者
Choi, Eun Jeong [1 ,2 ]
Han, Jung Yeol [1 ,3 ]
机构
[1] Korean MotherSafe Counselling Ctr, Pregnancy & Breastfeeding Med Informat Ctr, Seoul, South Korea
[2] Hanmaeum Changwon Hosp, Dept Obstet & Gynaecol, Chang Won, South Korea
[3] Inje Univ, Ilsan Paik Hosp, Goyang, South Korea
关键词
Isotretinoin; Pregnancy; Congenital abnormalities; Risk management; Abortion; induced;
D O I
10.5468/ogs.20247
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective Isotretinoin is commonly prescribed worldwide despite its notorious teratogenicity. A risk management program (RMP) was introduced in Korea to prevent isotretinoin use during pregnancy. Here, we evaluate the compliance of Korean women with the recommendations of the RMP. Methods This prospective cohort study was conducted between April 2019 and June 2020. Thirty-six and 82 patients received the prescription before and after the introduction of RMP, respectively. Results There was a significant difference in the total number of days for which isotretinoin was prescribed before and after the RMP was introduced (68.8 +/- 100.9 and 28.0 +/- 26.1 days, respectively). However, 1.43% (120/8,394) of the total patients contacted by the teratology information services were exposed to isotretinoin on an average. Conclusion The proportion of patients exposed to isotretinoin did not change, and there was no significant change in compliance, with the implementation of the RMP during the study period. Further studies are needed to evaluate the effectiveness of the RMP in the long term.
引用
收藏
页码:201 / 208
页数:8
相关论文
共 18 条
  • [1] What is the best approach to reducing birth defects associated with isotretinoin?
    Abroms, Lorien
    Maibach, Edward
    Lyon-Daniel, Katherine
    Feldman, Steven R.
    [J]. PLOS MEDICINE, 2006, 3 (11) : 1978 - 1983
  • [2] Patterns and utilization of isotretinoin for acne from 1984 to 2003:: is there need for concern?
    Azoulay, Laurent
    Oraichi, Driss
    Berard, Anick
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (08) : 667 - 674
  • [3] Isotretinoin, pregnancies, abortions and birth defects:: a population-based perspective
    Berard, Anick
    Azoulay, Laurent
    Koren, Gideon
    Blais, Lucie
    Perreault, Sylvie
    Oraichi, Driss
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (02) : 196 - 205
  • [4] Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era
    Charrow, Alexandra
    Xia, Fan Di
    Lu, Jessica
    Waul, Michael
    Joyce, Cara
    Mostaghimi, Arash
    [J]. PLOS ONE, 2019, 14 (03):
  • [5] Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic review
    Crijns, H. J. M. J.
    Straus, S. M.
    Gispen-de Wied, C.
    de Jong-van den Berg, L. T. W.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2011, 164 (02) : 238 - 244
  • [6] Fetal exposure to isotretinoin - An international problem
    Garcia-Bournissen, Facundo
    Tsur, Lilach
    Goidstein, Lee H.
    Staroselsky, Arthur
    Avner, Marina
    Asrar, Farhan
    Berkovitch, Matitiahu
    Strafacec, Gianluca
    Koren, Gideon
    De Santis, Marco
    [J]. REPRODUCTIVE TOXICOLOGY, 2008, 25 (01) : 124 - 128
  • [7] Continued occurrence of Accutane®-exposed pregnancies
    Honein, MA
    Paulozzi, LJ
    Erickson, JD
    [J]. TERATOLOGY, 2001, 64 (03) : 142 - 147
  • [8] iPLEDGE, 2016, COMM PREGN PREV
  • [9] Kim Nae Ry, 2018, Obstet Gynecol Sci, V61, P649, DOI 10.5468/ogs.2018.61.6.649
  • [10] A comparative review of the isotretinoin pregnancy risk management programs across four continents
    Kovitwanichkanont, Tom
    Driscoll, Tim
    [J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 2018, 57 (09) : 1035 - 1046